SXTP 60 Degrees Pharmaceuticals (SXTP) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001946563
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about SXTP
Insiders, 180 days
+$10.1K net bought
1 buyer
60 Degrees Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, 60 DEGREES PHARMACEUTICALS, INC. insiders bought a net $10.1K of stock across 22 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Dec 15, 2025.
- -43.3% median (-45.8% mean) 90-day return after 10 previous buys.
- The trade is 30.5% of the 24,131 shares held after it.
- No other insider bought within 30 days.
Insider activity: President and CEO DOW GEOFFREY S bought about $10.1K of SXTP on Jun 12, 2026, the largest insider purchase at the company since 2024.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Dec 11, 2025.
- -43.3% median (-47.4% mean) 90-day return after 9 previous buys.
- The trade is 16.2% of the 59,618 shares held after it.
- No other insider bought within 30 days.
Insider activity: President and CEO DOW GEOFFREY S bought about $7.7K of SXTP on Dec 15, 2025.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Dec 10, 2025.
- -46.6% median (-52.3% mean) 90-day return after 8 previous buys.
- The trade is 7.2% of the 49,948 shares held after it.
- No other insider bought within 30 days.
Insider activity: President and CEO DOW GEOFFREY S bought about $3.3K of SXTP on Dec 11, 2025.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Dec 9, 2024.
- -43.3% median (-52.7% mean) 90-day return after 7 previous buys.
- The trade is 20.2% of the 46,335 shares held after it.
- No other insider bought within 30 days.
Insider activity: President and CEO DOW GEOFFREY S bought about $8.9K of SXTP on Dec 10, 2025, the largest insider purchase at the company since 2024.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Dec 16, 2024.
- -74.2% median (-55.0% mean) 90-day return after 5 previous buys.
- The trade is 12.6% of the 15,816 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director XU CHERYL bought about $5.8K of SXTP on Jun 3, 2025.22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$10.1K over 180 days
more than 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+65.5% year over year
more than 81% of Pharma & Biotech
Margin
-732.5% net margin
below 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.5% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SXTP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-85.0%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SXTP: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in SXTP
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SXTP planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
2 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $10.1K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
SXTP financials
Revenue growth
+65.5%
XBRL, annual
Net margin
-732.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SXTP
| FY Dec 2025 | $1.0M |
| FY Dec 2024 | $607.6K |
| FY Dec 2023 | $253.6K |
| FY Dec 2022 | n/a |
| Jun 2026 | $207.9K |
| Mar 2026 | $162.1K |
| Dec 2025 | $303.4K |
| Sep 2025 | $437.6K |
| Jun 2025 | $100.9K |
| Mar 2025 | $163.6K |
| Dec 2024 | $230.8K |
| Sep 2024 | $135.3K |
At each fiscal year end
Single quarter
Net margin, TTM
-729.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SXTP
| FY Dec 2025 | -732.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -474.2% |
| Sep 2025 | -529.3% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$8.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SXTP
| FY Dec 2025 | -$7.0M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -$2.2M |
| Mar 2026 | -$2.8M |
| Dec 2025 | -$1.8M |
| Sep 2025 | -$2.1M |
| Jun 2025 | -$1.5M |
| Mar 2025 | -$1.6M |
| Dec 2024 | -$1.6M |
| Sep 2024 | -$1.7M |
At each fiscal year end
Single quarter
Debt to equity
0.06x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity SXTP
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | 0.04x |
| FY Dec 2023 | 0.03x |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.06x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.06x |
| Mar 2025 | 0.04x |
| Dec 2024 | 0.04x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-58.49x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt SXTP
| FY Dec 2025 | -44.83x |
| FY Dec 2024 | -36.23x |
| FY Dec 2023 | -30.29x |
| FY Dec 2022 | n/a |
| Jun 2026 | -58.49x |
| Mar 2026 | -53.28x |
| Dec 2025 | -44.83x |
| Sep 2025 | -45.30x |
| Jun 2025 | -42.45x |
| Mar 2025 | -40.70x |
| Dec 2024 | -36.23x |
| Sep 2024 | -27.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-321.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SXTP
| FY Dec 2025 | -196.4% |
| FY Dec 2024 | -178.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -321.6% |
| Mar 2026 | -169.5% |
| Dec 2025 | -196.4% |
| Sep 2025 | -152.3% |
| Jun 2025 | -286.1% |
| Mar 2025 | -181.3% |
| Dec 2024 | -178.5% |
| Sep 2024 | -126.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-191.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SXTP
| FY Dec 2025 | -132.4% |
| FY Dec 2024 | -117.4% |
| FY Dec 2023 | -82.9% |
| FY Dec 2022 | -476.2% |
| Jun 2026 | -191.6% |
| Mar 2026 | -118.9% |
| Dec 2025 | -132.4% |
| Sep 2025 | -113.0% |
| Jun 2025 | -183.7% |
| Mar 2025 | -142.8% |
| Dec 2024 | -117.4% |
| Sep 2024 | -95.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SXTP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-333.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SXTP
| FY Dec 2025 | -203.5% |
| FY Dec 2024 | -214.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -333.1% |
| Mar 2026 | -175.3% |
| Dec 2025 | -203.5% |
| Sep 2025 | -149.2% |
| Jun 2025 | -275.1% |
| Mar 2025 | -179.6% |
| Dec 2024 | -214.7% |
| Sep 2024 | -149.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SXTP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.2M
market value at close 2026-10-26 on 2026-08-14 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value SXTP
| FY Dec 2025 | $7.2M |
| FY Dec 2024 | $57.8M |
| FY Dec 2023 | $1.4B |
| FY Dec 2022 | n/a |
| Jun 2026 | $3.8M |
| Mar 2026 | $1.4M |
| Dec 2025 | $7.2M |
| Sep 2025 | $20.3M |
| Jun 2025 | $12.1M |
| Mar 2025 | $7.5M |
| Dec 2024 | $57.8M |
| Sep 2024 | $41.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-291.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield SXTP
| FY Dec 2025 | -81.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -190.0% |
| Mar 2026 | -176.8% |
| Dec 2025 | -81.3% |
| Sep 2025 | -28.2% |
| Jun 2025 | -46.1% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SXTP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.0M | $607.6K | $253.6K | $223.2K |
| Gross profit | $223.8K | $222.8K | -$221.0K | -$209.2K |
| Operating income | -$7.8M | -$9.7M | -$5.2M | -$1.8M |
| Net income | -$7.4M | -$7.9M | -$3.8M | -$6.2M |
| EPS (diluted) | -11.73 | -74.17 | -59.18 | -2.61 |
| Operating cash flow | -$6.8M | -$5.6M | -$4.5M | -$1.0M |
| Cash | $1.5M | $1.7M | $2.1M | n/a |
| Long-term debt | $144.0K | $147.1K | $150.0K | $16.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
SXTP Stock Sonar score 5/7 axes
Find similar shapesCompareSXTP ranks highest on growth (81st percentile) and insider conviction (60th), and lowest on profitability (9th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SXTP filings, in plain words
Are 60 Degrees Pharmaceuticals insiders buying or selling SXTP?
In the 180 days to 2026-10-28, 60 Degrees Pharmaceuticals insiders were net buyers, a net $10.1K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, 60 Degrees Pharmaceuticals insiders were net buyers of SXTP, a net $10.1K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
